The Stakes of Antibiotic Stewardship

Dr. Pol Vandenbroucke talks about what makes antibiotic stewardship so important to clinicians and researchers.

Segment Description: Dr. Pol Vandenbroucke, Chief Medical Officer for Pfizer’s hospital business unit, talks about what makes antibiotic stewardship so important to clinicians and researchers.

Related Coverage:

The AMR ACTION FUND

More than 20 biopharmaceutical companies are collaborating on an initiative to develop 2-4 antibiotics in 10 years in order to counteract antimicrobial resistance.The AMR Action Fund, an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), an international body representing the R&D pharmaceutical industry, was announced at simultaneous virtual launch events in Berlin and Washington, DC.“With the AMR Action Fund, the pharmaceutical industry is investing nearly $1 billion to sustain an antibiotic pipeline that is on the verge of collapse, a potentially devastating situation that could affect millions of people around the world,” Chairman and CEO of Eli Lilly and Company and President of IFPMA David Ricks said.

Read full story.